#USA #New York #Securities Fraud #Clinical Trial #Regeneron Pharmaceuticals

Regeneron Under Fire: Class Action Lawsuit Amid Stock Decline

Recently, Regeneron Pharmaceuticals, known for its innovative treatments, saw a staggering 9% drop in its stock price. This decline has prompted a class action lawsuit filed by a leading securities law firm, Bleichmar Fonti & Auld LLP, against the company. The lawsuit stems from claims of securities fraud due to misleading information provided to investors concerning the company’s Phase III clinical trial results for Fianlimab-Libtayo.

What Happened?

On April 29, 2026, before the stock market opened, Regeneron announced changes to the parameters of its Phase III trial for Fianlimab, raising concerns among investors. The company indicated that all enrolled patients would now require a minimum follow-up period of six months for data assessment. This announcement suggested that the trial was not yielding the hoped-for positive results, resulting in a sharp 6.2% drop in share price, moving from $731.77 to $686.36 per share.

A couple of weeks later, on May 15, 2026, Regeneron released another press statement revealing that the trial did not meet the statistical significance needed for its primary endpoint. Following this disclosure, the stock price plunged by an additional 9.8%, further diminishing investor confidence and pushing the price down to $629.68 per share by May 18, 2026.

The Allegations

The lawsuit claims that Regeneron, along with certain senior executives, misled investors about the potential success of the Fianlimab-Libtayo trial. During this period, Regeneron expressed “hope and confidence” in positive outcomes, asserting that the combination drug could potentially set a new standard for advanced melanoma treatment. However, the reality, as it turns out, indicated otherwise.

The suit specifically cites violations of the federal securities laws under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Investors maintain that had they been accurately informed about the trial’s limitations and failure to achieve significant results, many would not have purchased or continued holding the company’s stock.

Implications for Investors

Regeneron investors are urged to act swiftly, as the window to join the lawsuit as lead plaintiffs closes on September 14, 2026. The U.S. District Court for the Southern District of New York will hear the case, known as Cheathem v. Regeneron Pharm., Inc., et al., No. 26-cv-6026.

Bleichmar Fonti & Auld LLP has established itself in handling such class action lawsuits, regularly representing investors and holding corporations accountable for misleading practices that undermine shareholder value.

How to Proceed

Investors who believe they may have been affected by these developments are encouraged to reach out to BFA Law for further information and assistance. Given that legal representation will be on a contingency basis, affected parties will not incur upfront costs, alleviating financial burdens while seeking justice.

The firm has previously garnered significant recoveries for investors from major corporations, which builds its credibility and strengthens the case representation for current Regeneron investors. It’s an essential move for anyone looking to protect their financial interests while also holding companies accountable for their actions, especially in the high-stakes pharmaceutical sector.

For more information on the lawsuit and to see if you qualify to be a part of the class action, visit BFA Law’s website. Investors must act quickly to ensure their voices and grievances are heard in this legal battle against Regeneron Pharmaceuticals.